| Year |
Citation |
Score |
| 2020 |
Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, et al. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902983. PMID 32706640 DOI: 10.1200/Jco.19.02983 |
0.331 |
|
| 2020 |
Bell EH, Pugh SL, Fisher BJ, Lesser GJ, Macdonald DR, Fleming JL, McElroy JP, Becker AP, Rogers CL, Doyle TJ, Werner-Wasik M, Bahary J, Yu M, D'Souza D, Laack NN, et al. Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424. Journal of Clinical Oncology. 38: 2518-2518. DOI: 10.1200/Jco.2020.38.15_Suppl.2518 |
0.301 |
|
| 2019 |
Boru G, Grosel TW, Pilarski R, Stautberg M, Massengill JB, Jeter J, Singh A, Marino MJ, McElroy JP, Davidorf FH, Cebulla CM, Abdel-Rahman MH. Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer. Genes, Chromosomes & Cancer. PMID 30883995 DOI: 10.1002/Gcc.22752 |
0.321 |
|
| 2019 |
Fabian D, Bell EH, McElroy JP, Cui T, Fleming JL, Becker AP, Geurts M, Haque J, Robe PA, Chakravarti A. A preliminary comprehensive molecular-based nomogram for individualized estimation of survival in patients with newly diagnosed glioblastoma utilizing global microRNA expression data. Journal of Clinical Oncology. 37: 2044-2044. DOI: 10.1200/Jco.2019.37.15_Suppl.2044 |
0.321 |
|
| 2018 |
Beyer SJ, Bell EH, McElroy JP, Fleming JL, Cui T, Becker A, Bassett E, Johnson B, Gulati P, Popp I, Staszewski O, Prinz M, Grosu AL, Haque SJ, Chakravarti A. Oncogenic is differentially regulated in wild-type vs. mutant gliomas. Oncotarget. 9: 37097-37111. PMID 30647847 DOI: 10.18632/Oncotarget.26365 |
0.315 |
|
| 2018 |
Cui T, Bell EH, McElroy J, Becker AP, Gulati PM, Geurts M, Mladkova N, Gray A, Liu K, Yang L, Liu Z, Fleming JL, Haque SJ, Barnholtz-Sloan JS, Ligon KL, et al. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene. PMID 30559405 DOI: 10.1038/S41388-018-0601-9 |
0.302 |
|
| 2018 |
Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, et al. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. Jama Oncology. PMID 29955793 DOI: 10.1001/Jamaoncol.2018.1977 |
0.309 |
|
| 2018 |
Cui T, Gray A, Bell EH, McElroy J, Geurts M, Meng W, Haque J, Robe P, Chakravarti A. CSIG-24. miR-575 IS ASSOCIATED WITH WORSE SURVIVAL OF GBM PATIENTS AND ACTS AS A NOVEL ONCOGENE THROUGH TARGETING p27/CDKN1B AND BLID/BRCC2 Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.190 |
0.304 |
|
| 2018 |
Fleming J, McElroy J, Bell EH, Chang SM, Youssef EF, Hunter GK, Yung WA, Howard SP, Bovi JA, Bahary JP, Shih HA, Rabinovitch RA, Chen Y, Zhang P, Chakravarti A. Elevated MGMT Gene Expression is Independently Associated with Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.06.092 |
0.304 |
|
| 2017 |
Becker AP, Bell EH, Fleming J, McElroy JP, Fabian D, Beyer S, Salavaggione AL, Graham MK, Heaphy CM, Oehlke O, Staszewski O, Prinz M, Grosu A, Chakravarti A. Comprehensive assessment of ATRX mutation, protein expression, and alternative lengthening of telomeres (ALT) phenotype in grade II and III gliomas. Journal of Clinical Oncology. 35: 2064-2064. DOI: 10.1200/Jco.2017.35.15_Suppl.2064 |
0.306 |
|
| 2017 |
Cui T, Gray A, Liu Z, Geurts M, Robe P, McElroy J, Bell EH, Chakravarti A. Abstract 5726: A novel tumor-promoting role for miR-4516 in glioblastoma Cancer Research. 77: 5726-5726. DOI: 10.1158/1538-7445.Am2017-5726 |
0.301 |
|
| 2017 |
Bell EH, Zhang P, Aldape K, McElroy J, Mehta M, Fleming J, Liu Z, Coons S, Johnson D, Chakravarti A. OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.006 |
0.32 |
|
| 2016 |
Justiniano SE, McElroy JP, Yu L, Yilmaz AS, Coombes KR, Senter L, Nagy R, Wakely P, Volinia S, Vinco M, Giordano TJ, Croce CM, Saji M, Ringel MD. Genetic variants in thyroid cancer distant metastases. Endocrine-Related Cancer. PMID 27542854 DOI: 10.1530/Erc-16-0351 |
0.306 |
|
| 2016 |
Bell EH, McElroy JP, Fleming J, Timmers CD, Chakraborty AR, Salavaggione AL, Shaw EG, Aldape KD, Brachman D, Murtha AD, Won M, Mehta MP, Chakravarti A. Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs). Journal of Clinical Oncology. 34: 2017-2017. DOI: 10.1200/Jco.2016.34.15_Suppl.2017 |
0.301 |
|
| 2016 |
Chakraborty AR, Bell EH, Kriste S, Drendel V, McElRoy J, Werner M, Grosu A, Chakravarti A. Abstract 2781: Novel putative diagnostic methylation biomarkers for prostate cancer identified by whole genome DNA methylation profiling Cancer Research. 76: 2781-2781. DOI: 10.1158/1538-7445.Am2016-2781 |
0.303 |
|
| 2013 |
Clements A, McElroy J, Suarez A, Majumder S, Cohn D, Leone G. Abstract 1992: Is the ubiquitin ligase WWP2 playing a role in PTEN degradation in endometrial cancer. Cancer Research. 73: 1992-1992. DOI: 10.1158/1538-7445.Am2013-1992 |
0.325 |
|
| Show low-probability matches. |